Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trimethoprim

FDA-approved product (tablet, oral), marketed as Proloprim, Trimethoprim, Trimpex and 2 more.

Registered studies
50+
Lab records
56
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Trimethoprim
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Otitis media
  • Pneumocystosis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Trimethoprim and derivatives
FDA pharmacologic class
Dihydrofolate Reductase Inhibitor Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01EA01; FDA class Dihydrofolate Reductase Inhibitor Antibacterial

Repurposing investigation

Trimethoprim is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA79.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae76.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis9.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 7 of 8 lab records
  • E. coli: measured active in 32 of 33 lab records
  • K. pneumoniae: measured active in 7 of 12 lab records
  • M. tuberculosis: measured active in 0 of 3 lab records
Open Trimethoprim in ChEMBL Registered studies below
Show the 56 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trimethoprim with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • EAA-Guided AN69-oXiris and PMX-HP Therapy in Septic Patients

    NCT07788144 · start 2026-08-11

    Registered record
    Registry ID
    NCT07788144
    Conditions
    Hemoperfusion; Sepsis; ICU; Endotoxin Levels
    Interventions
    Adsorptive Hemofilter for Continuous Renal Replacement Therapy; Polymyxin B-Immobilized Hemoperfusion Cartridge
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-08-11
    Completion
    2028-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemoperfusion; Sepsis; ICU; Endotoxin Levels
    InterventionAdsorptive Hemofilter for Continuous Renal Replacement Therapy; Polymyxin B-Immobilized Hemoperfusion Cartridge
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

    NCT07431307 · start 2026-07

    Registered record
    Registry ID
    NCT07431307
    Conditions
    Ventilator Associated Bacterial Pneumonia (VABP); Hospital Acquired Bacterial Pneumonia (HABP); Blood Stream Infection; Meningitis, Bacterial; Ventriculitis, Infectious
    Interventions
    BV100 with 50 mg polymyxin B plus ceftazidime/avibactam; BV100 with 50 mg polymyxin B plus cefiderocol; Best Available Therapy (BAT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2028-07
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Bacterial Pneumonia (VABP); Hospital Acquired Bacterial Pneumonia (HABP); Blood Stream Infection; Meningitis, Bacterial +1 more
    InterventionBV100 with 50 mg polymyxin B plus ceftazidime/avibactam; BV100 with 50 mg polymyxin B plus cefiderocol; Best Available Therapy (BAT)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis

    NCT07495150 · start 2026-04-01

    Registered record
    Registry ID
    NCT07495150
    Conditions
    Blood-Brain Barrier; Bacterial Meningitis
    Interventions
    Intracalvariosseous injection vancomycin/tigecycline/polymyxin B; Intravenous injection vancomycin/tigecycline/polymyxin B; Conventional treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-04-01
    Completion
    2027-07-01
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlood-Brain Barrier; Bacterial Meningitis
    InterventionIntracalvariosseous injection vancomycin/tigecycline/polymyxin B; Intravenous injection vancomycin/tigecycline/polymyxin B; Conventional treatment
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Sebum Metabolomics and Lipidomics for Clinical Applications

    NCT07549828 · start 2026-04-01

    Registered record
    Registry ID
    NCT07549828
    Conditions
    Acne; Atopic Dermatitis; Seborrheic Dermatitis; Psoriasis; Healthy Subjects (HS)
    Interventions
    Sebutape sampling; Bacitracin/Polymyxin B/Neomycin ointment (Yentuogin ointment)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-04-01
    Completion
    2029-03-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne; Atopic Dermatitis; Seborrheic Dermatitis; Psoriasis +1 more
    InterventionSebutape sampling; Bacitracin/Polymyxin B/Neomycin ointment (Yentuogin ointment)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Phase I Study Comparing the Safety, Pharmacokinetics and Renal Effects of VRP-034 and Marketed Polymyxin B in Healthy Volunteers

    NCT07502144 · start 2026-04

    Registered record
    Registry ID
    NCT07502144
    Conditions
    Healthy Volunteers
    Interventions
    VRP-034 (Polymyxin B 500,000 IU); Commercially available Polymyxin B 500,000 IU (Poly-MxB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-04
    Completion
    2026-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionVRP-034 (Polymyxin B 500,000 IU); Commercially available Polymyxin B 500,000 IU (Poly-MxB)
    PhasePhase 1
    Registry statusNot yet recruiting

  • Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

    NCT07326540 · start 2026-03-27

    Registered record
    Registry ID
    NCT07326540
    Conditions
    Hospital Acquired Bacterial Pneumonia (HABP); Ventilator Associated Bacterial Pneumonia (VABP); Colistin Resistanrt ABC; Acinetobacter Baumannii-calcoaceticus Complex
    Interventions
    BV100 (300 mg); Polymyxin B; Colistin; Ampicillin-Sulbactam; MEROPENEM 2 grams TID
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-03-27
    Completion
    2028-03-30
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital Acquired Bacterial Pneumonia (HABP); Ventilator Associated Bacterial Pneumonia (VABP); Colistin Resistanrt ABC; Acinetobacter Baumannii-calcoaceticus Complex
    InterventionBV100 (300 mg); Polymyxin B; Colistin; Ampicillin-Sulbactam +1 more
    PhasePhase 3
    Registry statusRecruiting

  • ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

    NCT07759934 · start 2026-03-25

    Registered record
    Registry ID
    NCT07759934
    Conditions
    Ventilator-associated Bacterial Pneumonia (VABP); Hospital-acquired Bacterial Pneumonia (HABP)
    Interventions
    ASK0912 for Injection; ASK0912 for Injection; Polymyxin B Sulfate for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-03-25
    Completion
    2027-12-25
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator-associated Bacterial Pneumonia (VABP); Hospital-acquired Bacterial Pneumonia (HABP)
    InterventionASK0912 for Injection; ASK0912 for Injection; Polymyxin B Sulfate for Injection
    PhasePhase 2
    Registry statusRecruiting

  • A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers

    NCT07580586 · start 2026-03-22

    Registered record
    Registry ID
    NCT07580586
    Conditions
    Healthy Adult Participants
    Interventions
    BV100 (300 mg); Polymyxin B (50 mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-03-22
    Completion
    2026-12-30
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Participants
    InterventionBV100 (300 mg); Polymyxin B (50 mg)
    PhasePhase 1
    Registry statusRecruiting

  • A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection

    NCT06966284 · start 2025-11-26

    Registered record
    Registry ID
    NCT06966284
    Conditions
    Bacteremia Caused by Gram-Negative Bacteria; Bacterial Pneumonia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-11-26
    Completion
    2028-11-30
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia Caused by Gram-Negative Bacteria; Bacterial Pneumonia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • The Safety and Microbial Changes in the Use of Intranasal Neosporin®

    NCT07698938 · start 2025-02-13

    Registered record
    Registry ID
    NCT07698938
    Conditions
    Teste the Safety of (Polymyxin B Sulfate 500,000 IU, Bacitracin Zinc 40,000 IU, Neomycin Sulfate 0.35g Neomycin Base) Intranasally
    Interventions
    Intranasal application of Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-02-13
    Completion
    2025-03-23
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTeste the Safety of (Polymyxin B Sulfate 500,000 IU, Bacitracin Zinc 40,000 IU, Neomycin Sulfate 0.35g Neomycin Base) Intranasally
    InterventionIntranasal application of Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base
    PhaseNot applicable
    Registry statusCompleted

  • A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

    NCT06670872 · start 2024-10

    Registered record
    Registry ID
    NCT06670872
    Conditions
    Pneumonitis; Acinetobacter Baumannii
    Interventions
    Eravacycline combination therapy group
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-10
    Completion
    2026-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonitis; Acinetobacter Baumannii
    InterventionEravacycline combination therapy group
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB

    NCT06595979 · start 2024-06-25

    Registered record
    Registry ID
    NCT06595979
    Conditions
    Intracranial Infections
    Interventions
    Polymyxin B
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-06-25
    Completion
    2026-12
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Infections
    InterventionPolymyxin B
    PhaseNot recorded
    Registry statusRecruiting

  • Comparison of Epithelial Lining Fluid and Blood Pharmacokinetics and Pharmacodynamics of Intravenous and Intravenous Plus Nebulized Polymyxin B in Multidrug Resistant Bacteria Ventilator-associated Pneumonia Patients

    NCT06076603 · start 2023-07-01

    Registered record
    Registry ID
    NCT06076603
    Conditions
    Polymyxin B; Ventilator-associated Pneumonia; Multidrug Resistant Bacterial Infection; Pharmacogenomic Drug Interaction
    Interventions
    nebulized polymyxin B
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-07-01
    Completion
    2024-08-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolymyxin B; Ventilator-associated Pneumonia; Multidrug Resistant Bacterial Infection; Pharmacogenomic Drug Interaction
    Interventionnebulized polymyxin B
    PhaseNot recorded
    Registry statusUnknown

  • PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

    NCT05685615 · start 2023-04-20

    Registered record
    Registry ID
    NCT05685615
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    BV100 plus Polymyxin B; BAT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-04-20
    Completion
    2024-12-11
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionBV100 plus Polymyxin B; BAT
    PhasePhase 2
    Registry statusCompleted

  • Topical Antibacterial Agents for Prevention of COVID-19

    NCT05449392 · start 2022-09-01

    Registered record
    Registry ID
    NCT05449392
    Conditions
    COVID-19; SARS-CoV2 Infection
    Interventions
    Neosporin; Vaseline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-09-01
    Completion
    2023-09-22
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19; SARS-CoV2 Infection
    InterventionNeosporin; Vaseline
    PhasePhase 1
    Registry statusCompleted